Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zostavax Concomitant with Influenza Vaccine Study
NCT00231816Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Mar 2006
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, double-blind trial of varicella virus vaccine live in herpes zoster (HZ) (2 arms), sponsored by Merck & Co. Primary endpoint: Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses at 4 weeks. Started Sep 2005; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00231816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231816.